Heart Failure, Ventricular Dysfunction, Left
Conditions
Brief summary
The purpose of this study is to determine whether neuromuscular electrical stimulation can improve exercise tolerance for patients with heart failure and continuous dobutamine use in a hospital.
Interventions
Quadriceps and calf muscles of both legs were simultaneously stimulated using self adhesive surface rectangular electrodes. During all session period, the patients were maintained in the supine Fowler 45º position. Stimulation parameters were set up as follows: biphasic current of 40 Hz, 400-µs pulse duration, mode on-time 10s and off-time 20s and maximal amplitude of 60 mA. The stimulation intensity was progressively increased according to the patient tolerance until a muscular contraction was observed. Stimulation was performed twice a day; the session duration was 60 min.
each session consisted of breathing exercises and global active exercises of the upper and lower limbs in bed. The treatment was applied twice a day during the hospitalization period. The protocol was interrupted if the patient had signs or symptoms suggestive of poor tolerance to exercise: 1) cyanosis, pallor, dizziness, nausea or pre-syncope; 2) chest pain; 3) bradycardia; 4) a drop in systolic blood pressure \>15 mmHg in comparison to baseline; 5) an excessive rise in systolic blood pressure defined as \>200 mmHg; 6) a rise in diastolic blood pressure during exercise \>110 mmHg; 7) fatigue rated ≥6/10 on the perceived exertion Borg scale (PEB); and/or 8) electrocardiographic signs of cardiac ischemia or ventricular arrhythmias.
Sponsors
Study design
Eligibility
Inclusion criteria
* Advanced heart failure (Stage D - Left ventricle ejection fraction \<30%) * New York Heart Association class III-IV * Standard medical therapy for heart failure management * Continuous inotropic infusion
Exclusion criteria
* Unstable angina pectoris * Recent (6 months) acute coronary syndrome * Arrythmias * Chronic renal failure * Diabetes Mellitus * Peripheral vascular diseases * Inability to walk
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Functional capacity evaluated using the 6-minute walk test (6MWT) | Change from assessment at admission and at patient discharge | Functional capacity was evaluated using the 6-minute walk test (6MWT), by a single evaluator blinded to the group allotment, in accordance with American Thoracic Society criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in the intravenous inotropic support dosage | Change from the first day of the protocol and patient discharge | For all patients, the inotropic intravenous dose was adjusted daily by a single clinician (prescriber) blinded to the group allocation. Weaning from inotropic support was performed by the prescriber based on the improvement of clinical signs (level of consciousness, peripheral perfusion and blood pressure). |
Countries
Brazil